Health Canada authorization for XBB.1.5-adapted monovalent COVID-19 vaccine
Pfizer Canada ULC and BioNTech SE announced that Health Canada has authorized the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (Comirnaty Omicron XBB.1.5) for ages 6 months and older
The updated vaccine will be available in Canada as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. For children 6 months through 4 years of age the updated vaccine is authorized for administration as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose for those with a history of completion of a COVID-19 primary vaccination course.
The authorization of is based on the full body of previous clinical, non-clinical, and real-world evidence supporting the safety and efficacy of the Pfizer-BioNTech COVID-19 Vaccines. Further, the application included pre-clinical data on the neutralization potential of serum antibodies induced by the updated monovalent COVID-19 vaccine against multiple XBB-related sublineages, including XBB.1.5, XBB.1.16, XBB.2.3 and EG.5.1 (Eris).
Pfizer and BioNTech continue to monitor emerging SARS-CoV-2 strains and continue to conduct studies to monitor the vaccine’s effectiveness, including the recently emerged Omicron BA.2.86 (Pirola) variant and the globally dominant EG.5.1 (Eris) subvariant.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.